Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease
Enhanced Discrimination of Malignant from Benign Pancreatic Disease by Measuring the CA 19-9 Antigen on Specific Protein Carriers | PLOS ONE
![Cureus | Is There a Role of Elevated CA 19-9 Levels in the Evaluation of Clinical Characteristics of Mature Cystic Ovarian Teratomas? A Systematic Review and Meta-analysis Cureus | Is There a Role of Elevated CA 19-9 Levels in the Evaluation of Clinical Characteristics of Mature Cystic Ovarian Teratomas? A Systematic Review and Meta-analysis](https://assets.cureus.com/uploads/figure/file/84959/lightbox_6c2454701b0811eaa782efc044130466-Figure-3---24562.png)
Cureus | Is There a Role of Elevated CA 19-9 Levels in the Evaluation of Clinical Characteristics of Mature Cystic Ovarian Teratomas? A Systematic Review and Meta-analysis
![The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology](https://cdn.amegroups.cn/journals/pbpc/files/journals/1/articles/181/public/181-PB15-4535-R1.png/w300)
The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal - Ballehaninna - Journal of Gastrointestinal Oncology
![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlnkged-30.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. | Semantic Scholar The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/774e78614b2aab775f3493d19d9ef2cdd99429ad/3-Table1-1.png)
The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. | Semantic Scholar
![Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies](http://www.tropicalgastro.com/uploads/Untitlemscd-31.jpg)
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
![Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy](https://www.frontiersin.org/files/Articles/52319/fonc-03-00155-HTML/image_m/fonc-03-00155-g001.jpg)
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy
![Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - ScienceDirect Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1365182X15315859-gr1.jpg)
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - ScienceDirect
Columbia Asia Malaysia - Cancer Markers Screening Packages Columbia Asia Hospital - Miri (Valid until 31 December 2019) Get screened and track the cancer level at Columbia Asia Hospital – Miri. Male
![The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma | BMC Cancer | Full Text The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-016-2897-6/MediaObjects/12885_2016_2897_Fig2_HTML.gif)
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma | BMC Cancer | Full Text
![CA 19-9 level in different T stages, grades, depth of invasion, and in... | Download Scientific Diagram CA 19-9 level in different T stages, grades, depth of invasion, and in... | Download Scientific Diagram](https://www.researchgate.net/publication/225044947/figure/tbl1/AS:202694657613824@1425337580006/CA-19-9-level-in-different-T-stages-grades-depth-of-invasion-and-in-metastatic.png)
CA 19-9 level in different T stages, grades, depth of invasion, and in... | Download Scientific Diagram
![CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube](https://i.ytimg.com/vi/eOWd34Q2NoM/maxresdefault.jpg)
CA 19-9 tumor marker | pancreatic cancer diagnosis | tumor marker (Everything you need to know) - YouTube
![Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-65720-8/MediaObjects/41598_2020_65720_Fig3_HTML.png)